The use of botulinum toxin type A treatment in children with spasticity

Area of Science:

• Neurology
• Pediatrics
• Rehabilitation Medicine

Background:

• Current treatments for spasticity in children with cerebral palsy have limitations.
• There is a need for alternative therapeutic agents to manage pediatric spasticity.
• Cerebral palsy often involves significant motor impairments due to spasticity.

Purpose of the Study:

• To evaluate the efficacy of intramuscular botulinum toxin type A as an alternative treatment for spasticity in children with cerebral palsy.
• To assess the impact of botulinum toxin type A on motor function and gait in pediatric cerebral palsy patients.

Main Methods:

• Eighteen children (aged 3-17 years) with cerebral palsy received intramuscular botulinum toxin type A (6 U/kg).
• Outcomes were measured using the Ashworth Spasticity Scale, standardized videotape assessments, observational gait analysis, and walking velocity.
• Data were collected at baseline and post-treatment intervals.

Main Results:

• Statistically significant improvements (P < 0.001) were observed in the Ashworth Spasticity Scale and videotape assessments across all treated muscles.
• Gait analysis showed the most improvement at week 8 post-injection.
• Botulinum toxin type A injections led to enhanced walking velocity at all follow-up visits, particularly in the gastrocnemius-injected group (P < 0.001).

Conclusions:

• Intramuscular botulinum toxin type A demonstrates effectiveness in managing spasticity in children with cerebral palsy.
• The treatment showed particular efficacy at week 4 and when targeting the gastrocnemius muscle.
• Botulinum toxin type A represents a viable alternative therapeutic option for pediatric cerebral palsy management.